The short answer
Garlic may lower glucose modestly, but added hypoglycemia with insulin isophane has not been established. A product review is sensible because insulin isophane itself can cause low glucose.
What this answer covers
Oral Allium sativum supplements; garlic oils, aged extracts, powder, food portions and blends are not interchangeable.
- Supplement or preparation
- Allium sativum
- Medication ingredient
- insulin isophane
What the evidence supports
NIH guidance describes a small glucose-lowering effect of garlic supplements in diabetes. That supports considering the supplement when reviewing glucose changes, without proving that garlic causes clinically low glucose during insulin isophane treatment.
A diabetes trial is not an exact interaction trial
One study combined garlic with olive oil and several medicines, including glimepiride and metformin. It reported lipid improvements. It did not establish a garlic-insulin-isophane hypoglycemia effect, and the ingredients cannot be disentangled from that abstract.
Check the actual preparation
Supplement processing changes the exposure. A concentrated capsule or oil is not automatically equivalent to culinary garlic, and a blend may contain other glucose-active ingredients. The botanical name alone does not give a predictable effect.
Review changes in glucose
Discuss the exact product and amount with the diabetes team before starting or changing it. Follow your established glucose-monitoring and low-glucose treatment plan; do not adjust insulin isophane yourself. There is no established supplement-specific dose cut or protective spacing interval.
Evidence and practical considerations
Side effects & toxicity
Indirect preparation-specific glucose evidence does not establish added clinical hypoglycemia with insulin isophane.
- Exact scope
- Oral Allium sativum supplements; garlic oils, aged extracts, powder, food portions and blends are not interchangeable. with Insulin isophane RxCUI1605101 IN; human NPH subcutaneous suspension label bridge.
- Medication form and route
- subcutaneous insulin isophane; oral supplement
What remains uncertain
- No exact event rate or arbitrary dose adjustment.
Factors that may matter: Product; Dose; Meals; Other diabetes treatment.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed human NPH insulin
Hypoglycemia can be severe. Niacin may reduce glucose lowering. Changes in glucose-active treatments and meals can require monitoring and clinician review. Intravenous and pump use prohibited.
How this applies: RxCUI1605101 IN insulin isophane; human NPH formulation bridge explicit.
Human NPH labels inform the generic insulin-isophane ingredient. Not animal insulin, rapid analogs or automatically every premix. No herb-specific event rate.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed human NPH insulin
Hypoglycemia can be severe. Niacin may reduce glucose lowering. Changes in glucose-active treatments and meals can require monitoring and clinician review. Intravenous and pump use prohibited.
How this applies: RxCUI1605101 IN insulin isophane; human NPH formulation bridge explicit.
Human NPH labels inform the generic insulin-isophane ingredient. Not animal insulin, rapid analogs or automatically every premix. No herb-specific event rate.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 160adults with type 2 diabetes and dyslipidemia.
Combination intervention improved lipid measurements; inspected abstract does not establish hypoglycemia.
How this applies: Indirect for exact insulin isophane; study drug, supplement form and outcome retained.
Different sulfonylurea and multiple cointerventions; lipid outcomes cannot establish garlic-insulin-isophane low-glucose risk.
Source 4: federal health guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Garlic supplements may reduce glucose slightly in people with diabetes.
How this applies: Indirect for exact insulin isophane; study drug, supplement form and outcome retained.
Modest glucose lowering does not prove added clinical hypoglycemia with insulin isophane.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact isophane article with human NPH product bridge and source-specific clinical limits. | |
| Research summary published |
Article revision: 90535c5c36d96c1a
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.